Corpus ID: 79033343

Venclexta (Venetoclax) First BCL-2 Inhibitor Approved for High-Risk Relapsed Chronic Lymphocytic Leukemia

@inproceedings{Raedler2016VenclextaF,
  title={Venclexta (Venetoclax) First BCL-2 Inhibitor Approved for High-Risk Relapsed Chronic Lymphocytic Leukemia},
  author={Lisa A. Raedler and Rph and Medical Writer},
  year={2016}
}

References

SHOWING 1-5 OF 5 REFERENCES
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
  • 492
  • PDF
Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels.
  • 81
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
  • 521
  • PDF
How I treat CLL up front.
  • 206
  • PDF
Cancer . Net . Leukemia - chronic lymphocytic - CLL : statistics